Izmo Q1 FY27: consolidated PAT doubles, margins expand

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

IZMO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹937.85

prior close

₹962.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-3.1% vs market

IT Enabled Services peers, median of 74sector-0.3%-2.6% vs sector

On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.6 pts less than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

-1.3

15m

-2.8

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0+0.1-3.1-0.3-2.6

Next day

-2.4+0.5-2.9-0.9-1.5

-7.4-0.1-7.4-1.7-5.8

-7.6+0.4-8.0-1.1-6.5

-9.0+0.7-9.7-1.1-8.0

-10.6+0.9-11.6-0.4-10.3

-8.9+1.1-10.0-1.1-7.9

15d

-2.0+1.6-3.6-1.2-0.8

-2.4-0.7-1.7-3.2+0.7

-17.9-3.2-14.6-6.5-11.4

—————

UpDownMarket · Nifty Microcap 250Sector · IT Enabled Services peers, median of 74Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 results. Consolidated revenue grew 15.7% YoY to Rs. 6,538 lakh; PAT doubled to Rs. 1,219.50 lakh from Rs. 600.38 lakh. EBITDA margin expanded to 25.5% from 18.5%. Standalone remained muted with revenue at Rs. 994.30 lakh and PAT of Rs. 5.07 lakh. Also approved ESOP allotment of 17,745 shares, re-appointment of Kiran Soni as WTD, and voluntary delisting from Calcutta Stock Exchange.

Likely market impact

Consolidated earnings strength and margin gains are positives. Standalone weakness and minor ESOP dilution are negatives.